120 related articles for article (PubMed ID: 16351556)
1. Impact of a migraine management program on improving health outcomes.
Campinha-Bacote DL; Kendle JB; Jones C; Callicoat D; Webert A; Stoukides CA; Kaul AF
Dis Manag; 2005 Dec; 8(6):382-91. PubMed ID: 16351556
[TBL] [Abstract][Full Text] [Related]
2. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.
Dowson AJ; Tepper SJ; Baos V; Baudet F; D'Amico D; Kilminster S
Curr Med Res Opin; 2004 Jul; 20(7):1125-35. PubMed ID: 15265257
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of resource utilization and cost burden before and after an employer-based migraine education program.
Page MJ; Paramore LC; Doshi D; Rupnow MF
J Occup Environ Med; 2009 Feb; 51(2):213-20. PubMed ID: 19209043
[TBL] [Abstract][Full Text] [Related]
4. Reliability and validity of the migraine therapy assessment questionnaire.
Chatterton ML; Lofland JH; Shechter A; Curtice WS; Hu XH; Lenow J; Smullens SN; Nash DB; Silberstein SD
Headache; 2002; 42(10):1006-15. PubMed ID: 12453032
[TBL] [Abstract][Full Text] [Related]
5. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
Raggi A; Leonardi M; Bussone G; D'Amico D
Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
[TBL] [Abstract][Full Text] [Related]
6. Changing physician knowledge, attitudes, and beliefs about migraine: evaluation of a new educational intervention.
Patwardhan MB; Samsa GP; Lipton RB; Matchar DB
Headache; 2006 May; 46(5):732-41. PubMed ID: 16643575
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
[TBL] [Abstract][Full Text] [Related]
9. Qualities and health of lay trainers with migraine for behavioral attack prevention.
Mérelle SY; Sorbi MJ; Duivenvoorden HJ; Passchier J
Headache; 2010 Apr; 50(4):613-25. PubMed ID: 20456149
[TBL] [Abstract][Full Text] [Related]
10. Migraine education improves quality of life in a primary care setting.
Smith TR; Nicholson RA; Banks JW
Headache; 2010 Apr; 50(4):600-12. PubMed ID: 20148982
[TBL] [Abstract][Full Text] [Related]
11. Further validation of an individualized migraine treatment satisfaction measure.
Martin ML; Patrick DL; Bushnell DM; Gandra SR; Gilchrist K
Value Health; 2008; 11(5):904-12. PubMed ID: 18494756
[TBL] [Abstract][Full Text] [Related]
12. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes.
Cohen JA; Beall D; Beck A; Rawlings J; Miller DW; Clements B; Pait DG; Batenhorst A
Clin Ther; 1999 Jan; 21(1):190-204. PubMed ID: 10090435
[TBL] [Abstract][Full Text] [Related]
13. Migraine education brochures and patient-perceived satisfaction.
Medrano Martínez V; Callejo-Domínguez JM; Beltrán-Lasco I; Pérez-Carmona N; Abellán-Miralles I; González-Caballero G; Más-Sesé G; López-Hernández N; Pérez-Sempere A; Moltó-Jordá JM
Neurologia; 2015 Oct; 30(8):472-8. PubMed ID: 24975347
[TBL] [Abstract][Full Text] [Related]
14. Center of excellence for headache care: group model at Kaiser Permanente.
Blumenfeld A; Tischio M
Headache; 2003 May; 43(5):431-40. PubMed ID: 12752747
[TBL] [Abstract][Full Text] [Related]
15. Impact of pharmacist interventions on seeking of medical care by migraineurs.
Skomo ML; Desselle SP; Berdine HJ; O'Neil CK
J Am Pharm Assoc (2003); 2008; 48(1):32-7; quiz 1-4. PubMed ID: 18192128
[TBL] [Abstract][Full Text] [Related]
16. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey--Phase III.
MacGregor EA; Brandes J; Eikermann A; Giammarco R
Curr Med Res Opin; 2004 Jul; 20(7):1143-50. PubMed ID: 15265259
[TBL] [Abstract][Full Text] [Related]
17. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
18. Assessment of migraineurs referred to a specialist headache clinic in Singapore: diagnosis, treatment strategies, outcomes, knowledge of migraine treatments and satisfaction.
Soon YY; Siow HC; Tan CY
Cephalalgia; 2005 Dec; 25(12):1122-32. PubMed ID: 16305601
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society.
Pryse-Phillips WE; Dodick DW; Edmeads JG; Gawel MJ; Nelson RF; Purdy RA; Robinson G; Stirling D; Worthington I
CMAJ; 1997 May; 156(9):1273-87. PubMed ID: 9145054
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention.
Hoffmann W; Herzog B; Mühlig S; Kayser H; Fabian R; Thomsen M; Cramer M; Fiss T; Gresselmeyer D; Janhsen K
Ann Pharmacother; 2008 Dec; 42(12):1804-13. PubMed ID: 19001531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
